NAD+‑Dependent Mitochondrial Rescue of Cholinergic Myenteric Neurons Breaks the Inflammatory Feed‑Forward Loop in Aging Colonic Motility
Hypothesis
We propose that age‑related decline in NAD+ levels specifically impairs SIRT3‑mediated mitochondrial antioxidant signaling in cholinergic myenteric neurons, leading to excess ROS, neuronal loss, and reduced acetylcholine‑driven α7‑nAChR activation of M2 macrophages. This creates a feed‑forward inflammatory loop that accelerates motility decline, whereas nitrergic neurons retain higher basal NAD+ and SIRT3 activity, rendering them resistant.
Mechanistic Rationale
- Cholinergic myenteric neurons fire at higher frequencies and rely on calcium‑dependent acetylcholine release, which elevates mitochondrial calcium load and ROS production (2).
- NAD+ fuels SIRT3 deacetylase activity, which activates superoxide dismutase 2 (SOD2) and reduces mitochondrial ROS (4).
- Aging lowers colonic NAD+ levels, diminishing SIRT3 protection preferentially in high‑activity cholinergic cells, while nitrergic neurons, which fire less and express higher baseline SOD2, maintain redox balance (3).
- Loss of acetylcholine reduces α7‑nicotinic receptor signaling on macrophages, shifting the M1/M2 balance toward pro‑inflammatory M1 phenotypes that exacerbate neuron loss (2).
- Thus, NAD+ depletion links metabolic stress, selective cholinergic vulnerability, and inflammation in a single mechanistic chain.
Testable Predictions
- Aged mice will show lower NAD+ and SIRT3 activity in purified cholinergic myenteric neurons compared with nitrergic counterparts.
- Pharmacological or dietary NAD+ augmentation (e.g., nicotinamide riboside) will restore SIRT3 activity, decrease ROS, and preserve cholinergic neuron numbers in aged colons.
- Restored cholinergic signaling will increase α7‑nAChR‑mediated M2 macrophage polarization, reducing M1 markers and slowing motility decline as measured by the 3D‑Transit capsule (6).
- Nitrerergic neuron number and morphology will remain unchanged by NAD+ treatment, confirming selective cholinergic rescue.
Experimental Approach
- Isolate myenteric ganglia from young (3 mo) and aged (24 mo) mice; separate cholinergic (ChAT‑Cre; tdTomato) and nitrergic (nNOS‑GFP) subsets via FACS.
- Quantify NAD+ levels (enzymatic assay), SIRT3 activity (acetyl‑SOD2 Western blot), and mitochondrial ROS (MitoSOX fluorescence).
- Treat aged mice with nicotinamide riboside (400 mg/kg/day) or vehicle for 12 weeks; repeat neuronal counts (ChAT+, nNOS+), macrophage flow cytometry (CD86+ M1, CD206+ M2), and colonic transit using the 3D‑Transit capsule (6).
- Include a SIRT3 inhibitor control to verify pathway specificity.
- Statistical analysis: two‑way ANOVA with age and treatment factors; power analysis to detect 15 % neuronal difference (α=0.05, β=0.2).
Potential Implications
If NAD+ supplementation selectively protects cholinergic myenteric neurons and improves colonic motility, it would reveal a druggable axis connecting metabolic aging, neurodegeneration, and gut immunity. Conversely, failure to rescue cholinergic loss despite NAD+ repletion would refute the hypothesis and redirect focus to alternative drivers such as microglial‑like enteric macrophage intrinsic changes or extracellular matrix stiffening.